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Background: Phosphatidylinositol glycan biosynthesis class A protein (PIGA) is one of the enzymes involved in the
biosynthesis of glycosylphosphatidylinositol (GPI) anchor proteins, which function as enzymes, adhesion molecules,
complement regulators and co-receptors in signal transduction pathways. Until recently, only somatic PIGA mutations
had been reported in patients with paroxysmal nocturnal hemoglobinuria (PNH), while germline mutations had not
been observed, and were suspected to result in lethality. However, in just two years, whole exome sequencing (WES)
analyses have identified germline PIGA mutations in male patients with XLIDD (X-linked intellectual developmental
disorder) with a wide spectrum of clinical presentations.
Methods and results: Here, we report on a new missense PIGA germline mutation [g.15342986C>T (p.S330N)]
identified via WES followed by Sanger sequencing, in a Chinese male infant presenting with developmental arrest,
infantile spasms, a pattern of lesion distribution on brain MRI resembling that typical of maple syrup urine disease,
contractures, dysmorphism, elevated alkaline phosphatase, mixed hearing loss (a combination of conductive and
sensorineural), liver dysfunction, mitochondrial complex I and V deficiency, and therapy-responsive dyslipidemia with
confirmed lipoprotein lipase deficiency. X-inactivation studies showed skewing in the clinically unaffected carrier
mother, and CD109 surface expression in patient fibroblasts was 57% of that measured in controls; together these data
support pathogenicity of this mutation. Furthermore, we review all reported germline PIGA mutations (1 nonsense,
1 frameshift, 1 in-frame deletion, five missense) in 8 unrelated families.
Conclusions: Our case further delineates the heterogeneous phenotype of this condition for which we propose the
term ‘PIGA deficiency’. While the phenotypic spectrum is wide, it could be classified into two types (severe and less
severe) with shared hallmarks of infantile spasms with hypsarrhythmia on EEG and profound XLIDD. In severe
PIGA deficiency, as described in our patient, patients also present with dysmorphic facial features, multiple CNS
abnormalities, such as thin corpus callosum and delayed myelination, as well as hypotonia and elevated alkaline
phosphatase along with liver, renal, and cardiac involvement; its course is often fatal. The less severe form of PIGA
deficiency does not involve facial dysmorphism and multiple CNS abnormalities; instead, patients present with milder
IDD, treatable seizures and generally a longer lifespan.
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Glycosylphosphatidylinositol (GPI) is a glycolipid that is
synthesized and transferred to proteins in the membrane
of the endoplasmic reticulum [1]. Biogenesis of GPI an-
chored proteins is a conserved post-translational mecha-
nism in eukaryotes and is important for attaching these
proteins to the cell membrane, for protein sorting,
trafficking, and dynamics [1], and plays an essential role
in embryogenesis, neurogenesis, immune responses,
and fertilization [2-6]. To date, more than 20 phos-
phatidylinositol glycan biosynthesis protein (PIG) sub-
classes have been found to be involved in GPI anchor
biosynthesis and remodeling, and more than 150 pro-
teins carry GPI anchors [1]. An increasing number of
human diseases have been discovered to be due to muta-
tions in GPI biosynthesis genes.
PIGA (MIM 311770) encodes one of the seven proteins
involved in the transfer of N-acetylglucosamine (GlcNAc)
from UDP-N-acetylglucosamide (UDP-GlcNAc) to phos-
phatidylinositol (PI) to form GlcNac-PI [1]. This is the
first step of GPI anchor biosynthesis and takes place on
cytoplasmic side of the endoplasmic reticulum [1]. The
human PIGA gene is located on chromosome Xp22.2. It
spans 162 kb and the longest transcript (NP_002632.1) en-
codes for a protein of 484 amino acids expressed in a wide
variety of tissues including brain, liver, heart, and blood
cells [7]. Somatic PIGA mutations had been well docu-
mented in PNH [MIM 300818], an acquired hemolytic dis-
ease that manifests after clonal expansion of hematopoietic
cells with somatic PIGA mutations, where loss of CD55
and CD59 on erythrocytes causes complement-mediated
lysis [8-12]. Unlike somatic PIGA mutations, germline mu-
tations had not been observed until recently, and based on
experiments in mice [2] and in both murine [13] and hu-
man embryonic stem cells [14] it had been proposed that
germline PIGA mutations were lethal. In 2012, using an
X-chromosome exome next-generation sequencing screen,
Biesecker and colleagues identified a PIGA germline non-
sense mutation in two siblings with an early epileptic en-
cephalopathy with hypotonia, brain anomalies (myelination
abnormalities and a thin corpus callosum), cleft palate,
cardiac anomalies and early death [15]. Recently, four
additional clinical reports were published on patients with
germline PIGA mutations depicting a wide spectrum
of phenotypes and clinical diagnoses [7,16-18], inclu-
ding West syndrome [18], Multiple congenital anomalies-
hypotonia-seizures syndrome 2 (MCAHS2) [17,18] and
Ferro-Cerebro-Cutaneous syndrome (FCCS) [16]. Here, we
report a male patient with MRI brain abnormalities that re-
semble those of infants with maple syrup urine disease
(MSUD), multi-organ involvement, therapy-responsive
dyslipidemia, and reductions of mitochondrial respiratory
complexes I and V on Blue Native Gel (BNG) analysis.
Using WES, we identified in this patient a new missensePIGA germline mutation (g.15342986C>T, c.989G>A
[NM_002641], [p.S330N]), which will be referred to as
c.989G>A (p.S330N). We also review a total of 8 mutations
from 9 unrelated families, summarize clinical findings,
discuss genotype–phenotype correlations and identify com-
mon features that may be used to guide clinical identifica-
tion of patients with germline PIGA mutations.
Methods
This study was approved as part of our TIDEX gene
discovery project by the Ethics Board of the Faculty of
Medicine of the University of British Columbia (UBC
IRB approval H12-00067). Parents provided written in-
formed consent for publication of this report.
Case report
The male index (II:2) was the second child (Figure 1) of
non-consanguineous healthy Chinese parents with unre-
markable family history. Prenatal ultrasound showed
macrosomia and increased nuchal thickness. At 31 weeks
6 days gestation the biparietal diameter (BPD) was 89 mm
(97th centile), head circumference (HC) was 322 mm
(91st centile), abdominal circumference (AC) 330 mm
(>99th centile), and femur length (FL) was 64 mm (86th
centil) using B.C. Women’s Health Centre standard mea-
surements. At 22 weeks 3 days gestation BPD was 59 mm
(89th centile), HC was 215 mm (81st centile), AC was
213 mm (>99th centile), and FL 42 mm (89th centile).
Nuchal fold measurement at 20 weeks 3 days was 6.9 mm.
Maternal serum alpha-fetal protein (AFP) at 16 weeks
0 days was 49.1 ug/L which is 1.37 multiples of the mean
(MoM). Amniotic fluid AFP was 22.0 mg/L which is
3.61 MoM (with a risk assessment for open spina bifida of
1:11). Acetylcholinesterase electrophoresis appeared to be
normal. Prenatal amniocentesis revealed normal male
karyotype (46,XY). The boy was born at 38 weeks by Cae-
sarean section due to breech position with Apgar scores 5
and 9. His birth weight was 3975 g (>99th centile), length
was 51 cm (~75th centile) and head circumference
36.0 cm (98th centile). Dysmorphism was noted at birth
but became more apparent at a later age. Phototherapy
was administered during one week for unconjugated
hyperbilirubinemia.
The onset of epilepsy was 2.4 months; he had intract-
able seizures, which were initially classified as infantile
spasms (EEG showed modified hypsarrhythmia), evolv-
ing one month later to myoclonic seizures (EEG showed
suppression-burst-like pattern). He showed acquired
microcephaly at 8.7 months with an occipital frontal cir-
cumference (OFC) of 43 cm (~3rd centile). On exa-
mination at 14 months (Figure 1A), our patient showed
plagio-brachycephaly with the flattening of the right oc-
ciput greater than the left and a prominent right side of
the face, giving the appearance of facial asymmetry.
Figure 1 Patient images and pedigree of the family. (A) Facial features of the index patient at age 14 months. (B) Pedigree of the family with
new c.989G > A germline PIGA mutation. Sanger sequence verification is shown next to each member of the family. The deceased index was
confirmed to be hemizygous for the variant, while mother was confirmed to be a carrier; father and two unaffected brothers were confirmed to
have a normal copy of the gene. (C) MRI at age 4 months. Upper row, axial diffusion-weighted images (DWI), b = 1000 s/mm2; middle row,
corresponding apparent diffusion coefficient (ADC) maps; bottom row, axial T2-weighted images. There is restricted diffusion, evidenced by high
signal on DWI (arrows) and corresponding low signal on the ADC maps, at the level of the ponto-medullary tegmentum, superior cerebellar
peduncles, ventral midbrain, subthalamus, and inferior striatum. The same regions show abnormally elevated signal on the T2-weighted images.
The abnormalities selectively involve regions that are normally myelinated at this age and are consistent with intramyelin edema.
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and poorly defined eyebrows laterally. He had a round
face with flattening of the lateral profile, a broad fore-
head with shallow orbital ridges and supraorbital in-
dentations, most likely due to poor muscle function in
the temples. There was glabellar fullness, bilateral ptosis
with hypertelorism (intercanthal distance 3.0 cm; +2SD),
upslanted short palpebral fissures (palpebral fissure length
2.0 cm; −2.0 SD), and an interpupillary distance of
4.95 cm (90th centile). The outercanthal distance was
7.0 cm (−1 SD), within normal limits the short palpebral
fissures correct for the hypertelorism. The nose was short
(2.6 cm; −2 SD) with a low bridge, prominent lateral nasal
cartilage and anteverted nares. Ears were of normal size,
placement and form. Philtrum appeared relatively long(measured 1.2 cm) and smooth. There was retrognathia, a
tented upper lip with thickened alveolar overgrowth giving
the appearance of a high arched palate (intact). He showed
decreased facial expression. Redundant skin at the neck
was noted, along with contractures of the small and large
joints of upper and lower extremities; no pigmentation or
other cutaneous abnormalities were noted. From a neuro-
logic perspective there was profound global developmen-
tal delay with hyperekplexia, axial hypotonia, peripheral
hypertonia, rigidity and abnormal cry. There was de-
creased range of motion of all major joints including the
shoulders, elbows, wrist and fingers, as well as hips, knees
and ankles. He had hand splints for camptodactyly, deep
palmar creases (because of his fisting) and minimal move-
ment of his fingers.
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signal abnormalities with restricted diffusion at level of
the brainstem tegmentum, superior cerebellar peduncles,
subthalamus, and ventral striatum (Figure 1C), while
follow-up studies at 10 months and 2.5 years showed
progressive, severe cerebral and cerebellar atrophy asso-
ciated with diffuse leukoencephalopathy and thinning of
the corpus callosum. Serial MR spectroscopy showed
initially mildly elevated lactate peaks, normal on sub-
sequent imaging, as well as mild reduction of N-acetyl
aspartate in the mid brain.
His heart was mildly enlarged and ECG and Holter re-
vealed right ventricular hypertrophy and arrhythmia (AV
block, Wenckebach type I). He also had moderate hep-
atomegaly, apnea, unilateral hydronephrosis with renal
calculi, GI dysmotility which led to aspirations requiring
G-tube feeding, visual motor impairment and retinal
dystrophy (pale optic disc, flat macula, myopia, atrophic
retina; no cherry red spot), moderate conductive and
sensorineural hearing loss, stomatocytosis and hypere-
choic liver. The child died at the age of 3.4 years of car-
diac arrest; autopsy was not performed.
TORCH (toxoplasmosis, rubella, cytomegalovirus,
herpes simplex, and HIV) screening was negative. A
comprehensive metabolic investigation was initiated but
largely uninformative, with the following exceptions:
Plasma lipid profiling revealed markedly elevated tri-
glycerides at 85.31 mM (reference 0.4-1.5) and cho-
lesterol at 23.4 mM (reference 2.6-5.2), and absent
post-heparin lipoprotein lipase activity suggesting a
lipoprotein lipase deficiency. The abnormal lipid pro-
file normalized quickly with the implementation of a
medium-chain triglyceride enriched diet. Persistently
elevated alkaline phosphatase levels were also noted,
ranging from 364–649 U/L (Ref 110–320); calcium,
phosphate and vitamin D were within normal limits.
BNG Analysis of a muscle biopsy at 10 months showed
decreased amount of complex of I and V (at 30% and 10%
of a tissue-matched control sample, respectively). These
findings led to the initial clinical suspicion of a mito-
chondrial deficiency syndrome (lactates varied between
normal – 3.8 umol/L) or lipid storage disorder, and inves-
tigations were pursued accordingly.
Further molecular investigations yielded normal re-
sults including array-CGH analysis for copy number var-
iations (CNVs), mtDNA genome sequencing, targeted
gene sequencing of LPL, MECP2, ARX and a number of
nuclear encoded mitochondrial proteins. Elaborate bio-
chemical testing was completed with essentially unre-
markable results (ammonia, acylcarnitine profile, plasma
amino acids, very long chain fatty acids, transferrin iso-
electric focussing; urine organic acids, purines & pyrimi-
dines, mucopolysaccharides, oligosaccharides, bile acids).
The following enzymatic analyses yielded normal results:acid phosphatase, sphingomyelinase, arylsulphatase A, hex-
osaminidase A&B, biotinidase, chitotriosidase, galactosyl-
ceramidase, beta-glucosidase, beta-galactosidase, cathepsin
D, palmitoyl protein thio-esterase I, tripeptidyl peptidase I.
Filippin staining studies in fibroblasts showed mildly aty-
pical peri-nuclear vesicular accumulations of un-esterified
cholesterol but were considered non-diagnostic. Sphin-
gomyelinase enzymology and NPC1 and NPC2 sequen-
cing were all unremarkable. Iron staining of muscle was
negative.
Whole exome sequencing
With a profound IDD and an abnormal biochemical
phenotype, this patient met the inclusion requirements
for our TIDEX (Treatable Intellectual Disability Endea-
vour exome sequencing) gene discovery study. We iso-
lated genomic DNA samples from the peripheral blood
of the patient as well as parents and two unaffected male
siblings using standard techniques. WES was performed
for the index patient and his unaffected parents using
the Agilent SureSelect kit and Illumina HiSeq 2000
(Perkin-Elmer, Santa Clara, California, USA). An in-
house designed bioinformatics pipeline [19] was used to
align the reads to the human reference genome version
hg19 and to identify and assess rare variants for their
potential to disrupt protein function. The candidate vari-
ants were further confirmed using Sanger re-sequencing
in all the family members. Deleteriousness of the candi-
date variants was assessed using Combined Annotation–
Dependent Depletion (CADD) scores [20], PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/) [21] and SIFT
(Sorting Intolerant From Tolerant; (http://sift.jcvi.org/)
[22]. Protein alignment was generated using T-Coffee
(http://www.tcoffee.org/) [23] and analyzed using Gene-
Doc http://www.nrbsc.org/gfx/genedoc/gdpaf.htm/). Only
those variants predicted to be “functional” (missense, non-
sense and frameshift changes, as well as in-frame deletions
and splice-site effects) were subsequently screened under
a series of inheritance models.
X-inactivation studies
X-chromosome inactivation (XCI) was assayed in the
unaffected mother using the allelic ratio of methylated
alleles at the Androgen Receptor (AR) locus [24] as de-
scribed previously [25]. The degree of allelic bias in
terms of which X chromosome is inactivated can range
from 50% (completely random) to 100% (completely
skewed).
Functional analysis
To provide evidence for pathogenicity of the identified
mutation, patient and control skin fibroblasts were
analyzed by flow cytometry for surface expression of
CD109, a GPI-anchored protein. Cells were washed with
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5 mM EDTA (Gibco) in PBS and washed in 2% FBS
(Gibco)/PBS. Cells were then stained for 20 minutes at
4°C with CD109-PE (BioLegend) and PE mouse IgG1, κ
isotype control (BioLegend). Data were acquired using a
BD™ LSR II flow cytometer and analyzed using FlowJo
v8.8.4 (Tree Star). Protein expression was determined by
Western blot analysis. Briefly, skin fibroblasts were har-
vested and lysed (cell lysis buffer, Cell Signaling) in the
presence of protease inhibitor cocktails (Roche). Equal
amounts of protein were separated by SDS-PAGE, trans-
ferred to PVDF membrane and blocked with 5% BSA.
Protein expression was detected using an anti-PIG-A
(clone H-6, Santa Cruz) primary antibody. After wash-
ing, bound antibody was detected with HRP-conjugated
anti-mouse secondary antibody and Novex ECL chemi-
luminescent substrate (Invitrogen).
Results
New PIGA germline mutation in our patient with
multisystem disease
In the WES data we identified four rare homozygous, four
rare hemizygous and eight rare compound heterozygous
candidates; we did not identify any rare denovo variants
affecting protein-coding regions. Of those, only three mis-
sense variants were considered functional candidates.
COX7A2 (encoding the nuclear-coded polypeptide chains
of cytochrome c oxidase, the terminal oxidase in mito-
chondrial electron transport (MIM123966)), and C19orf12
(associated with neurodegeneration with brain iron accu-
mulation 4 (MIM 614298)), and Spastic Paraplegia 43 AR
(MIM 615043) phenotypes were subsequently ruled out as
Sanger sequencing showed the same recessive genotype in
both clinically unaffected brothers. The final candidate,
PIGA (g.15342986C>T c.989G>A [NM_002641], [p.S330N])
was a novel missense variant not found in more than 250
in-house exomes, dbSNP 138, NHLBI Exome Sequencing
Project or Exome Aggregation Consortium (ExAC). The
variant is predicted to be the most deleterious of all candi-
dates using the CADD scores [20]. It affects a highly con-
served amino acid (Figure 2) and is predicted to be
damaging by both PolyPhen-2 [26] and SIFT [22]. The
Sanger re-sequencing of the genomic DNA confirmed that
index II-2 is hemizygous for the C to T transition, mother
is the carrier, while the two unaffected brothers do not
have this variant (Figure 1B). Finally, X-inactivation stu-
dies showed the pattern of X-inactivation to be 94.5%
skewed in the unaffected carrier mother. Together, the
genetic analysis based on WES shows that the c.989G>A
(p.S330N) variant is a new variant, it affects an evolution-
arily conserved amino acid of PIGA resulting in a deleteri-
ous change (Figure 2), and segregates with disease in the
family (Figure 1B). Functional characterization of the va-
riant showed normal expression of PIGA protein in skinfibroblasts (Figure 3A) but there was a 44% reduction in
the surface expression of GPI-anchored CD109 (Figure 3B).
The mother of the patient had a normal complete blood
cell count and no evidence of red cell hemolysis on periph-
eral blood smear. A standardized flow cytometric method
for screening PNH measuring CD55 and CD59 expression
on erythrocytes was negative.
Discussion
WES revealed a novel, likely pathogenic variant in the
PIGA gene in our patient with multisystem disease in-
cluding early onset intractable epilepsy, severe IDD, fa-
cial dysmorphism, conductive and sensorineural hearing
loss and visual impairment, joint contractures and hep-
atic and renal involvement.
To date, seven germline mutations in PIGA have been
discovered using WES technologies in eight unrelated
families [7,15-18]. Locations of the pathogenic variants are
listed in Table 1 and highlighted on a multi-sequence
alignment of PIGA proteins in Figure 2. PIGA germline
mutations have been found in XLIDD male patients with a
wide spectrum of clinical diagnoses (Table 1). Mothers of
the affected males were confirmed to be carriers in all ex-
cept for one family (Table 1) where the DNA for the
mother was unavailable [18].
The phenotypic spectrum of PIGA germline mutations
has shown wide variation, as reflected by the range of
clinical diagnoses summarized in Table 1. However, a
common set of characteristic features, shared by our pa-
tient, has emerged including infantile spasms with hyp-
sarrhythmia on EEG (Table 1) and IDD. Generally, the
phenotypic spectrum could be classified into two types
(severe and less severe), as proposed by Kato et al. [18],
where presence of facial dysmorphism correlates very
well with the more severe spectrum of clinical manifes-
tations (Table 1). In addition to early onset infantile
spasms with hypsarrhythmia on EEG, IDD and profound
developmental delay, the patients with more severe man-
ifestations of PIGA germline mutations (patients: IV-2,
IV-4 [15], III-1 [17], III-9 [16], 1, 2, and 5 [18], and our
case [this report]) also present with dysmorphic facial
features, multiple CNS abnormalities, such as thin corpus
callosum and delayed myelination, as well as hypotonia
(Table 1). Other phenotypes such as polyhydramnios, joint
contractures, hyperreflexia, cardiac anomaly, severe devel-
opmental delay and elevated alkaline phosphatase are also
recurrently seen in these patients, while additional pheno-
types appear to be allele-specific (Table 1). Unlike patients
with severe phenotypes, the less severe form of PIGA germ-
line mutations (patients: IV-2 [7], 3 and 4 [18]) did not in-
volve facial dysmorphism and multiple CNS abnormalities,
but did present with early onset of infantile spasms with
hypsarrhythmia on EEG (Table 1), and generally longer life
span marked by IDD, treatable seizures and PDD (Table 1).
Figure 3 PIGA expression and surface expression of GPI-AP (CD109) in patient skin fibroblasts. (A) Western Blot showing similar expression
of PIGA in patient versus control fibroblasts; β-actin was used as a loading control. (B) Flow cytometry analysis of patient’s fibroblasts revealed reduced
expression (56%) of GPI-AP (CD109) when compared to control fibroblasts. Isotype controls are included to show specific binding.
Figure 2 A multi-sequence alignment of PIGA proteins and distribution of all known germline mutations. The PIGA protein sequences
were generated using depicted transcript identifiers from: Homo sapiens (human), Mus musculus (mouse), Bos taurus (cow), Gallus gallus (chicken),
Danio rerio (zebrafish), Caenorhabditis elegans (worm) and Saccharomyces cerevisiae (yeast). Protein alignment was generated using T-Coffee [23]
and analyzed using GeneDoc.
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feature of PIGA mutations, as is seen with many other
defects in GPI-anchor biosynthesis. Chiyonobu et al.
[27] hypothesized that these seizures are due to intra-
cellular pyridoxal phosphate deficiency secondary to the
loss of membrane bound alkaline phosphatase, which is
required to initiate pyridoxal-phosphate for transit of the
plasma membrane (after which it is rephosphorylated).
Given that GABA synthase requires intracellular
pyridoxal-phosphate, it is the intracellular GABA defi-
ciency which likely leads to the onset of seizures [27].
Additional features are frequently reported in patients
with the severe form of PIGA germline mutations, as pro-
posed by [18] including: hypotonia (7/8 patients with
available data), elevated alkaline phosphatase (5/5 patients
with available data), hyperreflexia (5/5 patients with avail-
able data), joint contractures (5/6 patients with available
data), cardiac anomalies (4/4 patients with available data)
and polyhydramnios (4/8 patients with available data) pos-
sibly due to dysphagia associated with hypotonia. The pla-
giocephaly facial dysmorphism in our and published cases
is likely secondary to the hypotonia, causing facial asym-
metry and distortion of proportions as well as secondary
contractures. Our patient specifically appears to have a
short nose with anteverted nares and a depressed nasal
bridge, seen as the triangular structure at the base of the
nose (Figure 1A). This feature appears to be present in the
more severely affected published cases [18]. Additional
features such as dental problems (e.g. microdontia, de-
layed eruption) [16,17], liver problems [15,16,18] visual
impairment and deafness [16] appear to be recurrent as
well (Table 1). On the other hand some features, such as
accelerated linear growth and obesity [17], CNS iron
deposition and ichthyosis [16], dyslipidemia and stoma-
tocytosis (in the patient reported here) are reported
only once. The cause of death in patients with PIGA
mutations has been mainly due to cardiac arrest, pneu-
monia and respiratory failure (Table 1). Although the
life span of the patients affected with less severe muta-
tions is generally longer, there is a great degree of
variability in life-span even in patients with the same
germline mutation [15,16,18,28].
Reports of brain MRI findings in PIGA deficiency de-
scribe white matter immaturity with insufficient myelin-
ation, cerebral atrophy, thinning of the corpus callosum,
and a small cerebellum [7,15,18]. Cerebral atrophy ap-
pears to progress rapidly and is associated with abnor-
mal white matter myelination, consistent with an early
neurodegenerative process [18]. Our case showed a simi-
larly rapid progression, with an established cerebral atro-
phy associated with disrupted subcortical myelination at
age 2.5 years. However, the most remarkable finding in
the early stages of the disease was restricted diffusion in
the brainstem tegmentum, superior cerebellar peduncles,subthalamus, and ventral striatum, indicative of intra-
myelin edema, involving selectively white matter regions
that are already physiologically myelinated at birth. Kato
et al. [18] also reported three cases showing restricted
diffusion at the brainstem, basal ganglia, thalamus, and
deep white matter. Interestingly, these findings are re-
markably similar to those of the classical form of MSUD,
an amino aciduria caused by deficiency of branched
chain α-keto acid dehydrogenase enzyme, in which brain
MRI of affected newborns or infants studied during
stages of metabolic decompensation shows prominent
signal changes and swelling within myelinated brain
areas representing intramyelin edema, caused by a deficit
of Na+/K+ ATPase activity as a result of impairment in
energy production secondary to branched chain amino
acids accumulation [29,30]. In particular, the findings of
our case are remarkably similar to those shown in figure
six in the report by Rossi and Biancheri [31], implicating
that the diagnosis of PIGA deficiency could be suggested
in neonates with similar brain MRI findings and un-
remarkable plasma amino acid and urine organic acid
profiles. An explanation for the similarities remains
speculative; the typical lesions in the newborn with
MSUD involve preferentially those structures that are
already myelinated at birth and thus with higher meta-
bolic demands and most vulnerable to the energy defi-
ciency and toxicity of branched-chain 2-oxo acid(s). In
PIGA deficiency, although toxins have not yet been iden-
tified, we speculate that mitochondrial and thus energy
deficiency could similarly play a role in the etiology of
the observed intra-myelin edema. Regardless of the im-
plicated pathophysiologic mechanism, identification of
similarities in the lesion distribution and appearance on
MRI represents the foundation of the pattern recogni-
tion approach, whereby neuro-imaging can guide the
diagnostic process to reduce the number of unnecessary
tests and time to diagnosis [32]. PIGA catalyzes the first
step in GPI biosynthesis and it is anticipated that even a
partial defect in activity will have a significant impact on
the localization and functionality of a broad range of
GPI-anchored proteins. The elevation in serum alkaline
phosphatase reported here as well as in the majority of
other PIGA deficient cases (likely correlated with sever-
ity of the disease) (Table 1) as well as other PIG deficien-
cies results from the secretion of GPI-deficient alkaline
phosphatase (normally membrane-anchored) and may
serve as a diagnostic clue. Normal levels of alkaline
phosphatase however, do not rule out the condition, as
evidenced by the mild case reported by Belet et al. [7].
The hypertriglyceridemia and serum LPL deficiency ob-
served in our patient is also likely caused by abnormal
GPI biosynthesis. LPL release from endothelial cells in re-
sponse to heparin stimulation requires the activity of
GPIHBP1 (GPI-anchored high-density lipoprotein binding
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anchored protein lead to hypertriglyceridemia and
non-detectable serum lipoprotein lipase [33]. The GPI
biosynthesis defect resulting from PIGA mutation likely
leads to a secondary GPIHBP1 deficiency, although fur-
ther evaluation is required to confirm this mechanism, as
a similar defect has not been described or investigated in
other individuals with PIGA defects.
The germline mutational spectrum for PIGA com-
prises various mutation types including one nonsense
mutation [15,18], one frameshift mutation that results in
production of 36 amino acids shorter PIGA protein [7],
one small in-frame deletion [16], and four missense
mutations [17,18] (Figure 2). PIGA protein is well con-
served from yeast to human (Figure 2), and all of the
reported mutations, except for c.76dupT, occurred at
evolutionarily conserved or semi-conserved amino acids
(Figure 2). The c.76dupT frameshift mutation occurs in
the non-conserved part of the protein but results in
translation of the PIGA protein using a cryptic start site
at amino acid position 37 producing shorter PIGA
protein with the majority of the conserved amino acids
intact [7]. One mutation, c.1234C>T, was recurrent
(Table 1) [15,18].
Studies in mice revealed that complete disruption of
the PIGA gene results in early embryonic lethality in
males, while in carrier female mice late embryonic le-
thality is observed [3]. Based on these studies, it is
believed that complete loss of PIGA function is lethal in
humans. A number of studies suggest that the human
mutations identified to date result in reduced, but not
absent, PIGA activity and using the flow cytometry of
blood granulocytes method, Kato et al. [18] showed that
the phenotype severity of the PIGA germline mutations
appeared to correlate with genotype and the residual func-
tional activity of the PIGA protein [18]. Functional studies
on the truncating c.1234C>T mutation (p.R412X) suggest
that small amounts of full length PIGA protein were gen-
erated by the read through of the premature termination
codon (PTC) [15,18]. During two stages of eukaryotic
translation (elongation and termination), aminoacyl-
tRNAs and termination factors compete for codon bin-
ding. When aminoacyl-tRNAs supersedes, read through of
the termination codon occurs, which allows the gener-
ation of the full-length polypeptide. Depending on the
amino acid inserted during the read through, the resulting
protein may have normal or partial activity. Studies on base
level of read through reveal 10 fold higher frequency at
PTCs (<1%) [34,35] when compared to naturally occurring
stop codons (<0.1%) [36,37]. In addition to c.1234C>T
(p.R412X), studies on the c.328_330delCCT (p.L344Del)
mutation revealed reduced GPI-anchored proteins on the
patient’s granulocytes, while normal levels were observed
on the red blood cells and monocytes, suggesting reducedbut not absent PIGA activity [16]. Complementation assays
using the c.76dupT frameshift mutation confirmed partial
function of the shorter PIGA protein, which was sufficient
to rescue surface expression of CD59 in a PIGA null cell
line [7]. Consistent with previous findings, our patient’s
mutation also led to reduced surface expression of the
GPI-anchored protein CD109 on skin fibroblasts, despite
normal levels of protein expression.
Patients with PIGA germline mutations share key pheno-
typic features with patients carrying mutations in genes en-
coding various PIG family members, including IDD,
seizures, hypotonia, growth defects, congenital abnorma-
lities, heart defects, and abnormal metabolic profiles. For
example, inherited glycosylphophatidylinositol deficiency
(MIM 610293) resulting in portal- and hepatic-vein throm-
bosis and absence seizures was found to be due to muta-
tions in PIGM gene (MIM610273) [5]. Hyperphosphatasia
Mental Retardation syndrome (HPMRS, MIM 239300,
MIM 214749, and MIM 614207), also known as Mabry
syndrome, was found to be associated with PIGV (MIM
610274), PIGO (MIM 614730),PGAP2 (MIM 615187) and
PGAP3 (MIM 611801) mutations [38-42]. HPMRS is
characterized by elevated alkaline phosphatase levels, IDD,
seizures, hypotonia, and facial dysmorphic features [38].
CHIME syndrome (MIM 280000), also known as Zunich
Neuro-Ectodermal syndrome was found to be due to mu-
tations in PIGL (MIM 605947). Individuals with CHIME
syndrome present with colobomas, congenital heart de-
fects, early onset migratory ichthyosiform dermatosis, IDD,
and ear anomalies, including conductive and sensori-
neural hearing loss [43]. PIGT mutations cause congenital
anomalies-seizures-hypotonia type 3, with hypophosphata-
sia as key feature [44,45]. The wide spectrum of human
conditions associated with mutations in PIG genes reflects
their role in multiple developmental processes and resem-
bles the diversity of clinical features associated with glyco-
sylation pathways deficiencies [43].
A variety of clinical case descriptors have been applied
to individuals with germline PIGA mutations (Table 1).
However, given the varied clinical spectrum reported to
date, it appears that the multi-system roles of GPI-
anchored proteins and private nature of most of the
PIGA mutations identified will preclude the definition of
a common feature set. To unify further reports on this
intriguing condition, we advocate for the use of ‘PIGA
deficiency’.
Careful patient phenotyping will continue to shed light
on the (patho-) physiologic roles of PIGA deficiency; for
example, its relation with mitochondrial structure and
function. We are the first to report severely reduced
amount of mitochondrial complexes (specifically I and
V), but other mitochondrial defects have been reported
in PIGA mutations: e.g. ‘disorganized mitochondria’ in
FCC syndrome [16] and ‘abnormal ATP production’ in a
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In fact, recent publications show that several mitochon-
drial membrane proteins are either modified with GPI
anchor addition or associated with GPI anchored pro-
teins, a process required for their proper function [46].
Therefore, it is of great interest to test patients with the
PIGA mutations for mitochondrial defects and vice
versa, to test the patients with unexplained mitochon-
drial phenotypes for potential PIGA mutations, espe-
cially in the presence of features described here.
Conclusions
Based on the patient descriptions published to date, in-
tractable, infantile onset epilepsy with suppression burst
and/or hypsarrhythmia in patients with X-linked IDD of
unknown etiology should prompt clinicians to consider
germline mutations in the PIGA, particularly in a patient
with elevated serum alkaline phosphatase. The additional
presence of dysmorphic facial features, CNS abnorma-
lities, hypotonia, heart defects, dyslipidemia/lipoprotein
lipase deficiency, or signs of intra-myelin edema on brain
MRI, may increase the likelihood of mutations in PIGA
specifically, and PIG family members in general. Flow cy-
tometry of blood granulocytes has also proven a useful
test for levels of GPI-anchored proteins expression in pa-
tients with PIGA mutations [7,15,16,18].
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